Circulating Tumor Cell-Free DNA as Prognostic Biomarker in Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: The CORELAB Experience
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26020611 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Stefania Gelmini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Carcinoma, Non-Small-Cell Lung, Biomarkers, Tumor, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regione Toscana, INSTAND-NGS4P, Regione Toscana, Bando Ricerca Salute 2018.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The expression level of Programmed Death-Ligand 1 (PD-L1) determined by the immunohistochemical method is currently approved to test the potential efficacy of immune-checkpoint inhibitors and to candidate patients with Non-Small Cell Lung Cancer (NSCLC) for treatment with immunotherapeutic drugs. As part of the CORELAB (New prediCtivebiOmaRkers of activity and Efficacy of immune checkpoint inhibitors in advanced non-small cell Lung cArcinoma) project, aimed at identifying new predictive and prognostic biomarkers in NSCLC patients receiving immunotherapeutic drugs, we investigated the role of circulating tumor DNA (ctDNA) molecular characterization as an additional predictive biomarker. We analyzed plasma ctDNA by targeted Next Generation Sequencing in a subset of 50 patients at different time points. ctDNA content was inversely correlated with the clinical outcome both at a baseline and after 2 months of treatment. OS was significantly higher in patients with ≥50% ctDNA reduction. TP53 and KRAS were the most frequently mutated genes, and patients with KRAS and/or TP53 mutations showed worse outcomes than patients without detectable variants or with mutations in other genes. Fewer common variants were found in BRAF, EGFR, MAP2K1, MET, NRAS, and PIK3CA genes. Our data demonstrated that molecular characterization of ctDNA and also its quantitative evaluation could serve as a dynamic, real-time prognostic, and predictive biomarker, enabling regular molecular monitoring of therapy efficacy in support of other medical examinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.
- Molecular and Clinical Biochemistry Laboratory, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy.
- Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
- Radioterapy Unit, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy.
ORCID-Profile: Irene Mancini, Marco Banini, Pamela Pinzani
Förderung
- Regione Toscana
- INSTAND-NGS4P
- Regione Toscana, Bando Ricerca Salute 2018
Zitieren
APA
Gelmini, S., Calabri, A., Mancini, I., Comin, C. E., Pasini, V., Banini, M., Scotti, V., & Pinzani, P. (2025). Circulating Tumor Cell-Free DNA as Prognostic Biomarker in Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: The CORELAB Experience. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26020611
Vancouver
Gelmini S, Calabri A, Mancini I, Comin CE, Pasini V, Banini M, et al. Circulating Tumor Cell-Free DNA as Prognostic Biomarker in Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: The CORELAB Experience. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26020611
BibTeX
@article{Gelmini2025,
author = {Gelmini, Stefania and Calabri, Adele and Mancini, Irene and Comin, Camilla Eva and Pasini, Valeria and Banini, Marco and Scotti, Vieri and Pinzani, Pamela},
title = {Circulating Tumor Cell-Free DNA as Prognostic Biomarker in Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: The CORELAB Experience},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26020611}
}
EUVIMED